Optimal method for the investigation of suspected lung cancer; Endobronchial Ultrasound versus Computerised Tomography (CT)-guided lung biopsy for the diagnosis of lung cancer.

• Register: ANZCTR
• Last refreshed on: 22 February 2013
• Main ID: ACTRN12607000514404
• Date of registration: 09/10/2007
• Primary sponsor: Hospital Royal Melbourne Hospital
• Public title: Optimal method for the investigation of suspected lung cancer; Endobronchial Ultrasound versus Computerised Tomography (CT)-guided lung biopsy for the diagnosis of lung cancer.
• Scientific title: Approach to the investigation of lung cancer; A Randomized Controlled Trial of Endobronchial Ultrasound versus CT-guided Core Needle Biopsy for the diagnosis & staging of lung cancer.
• Date of first enrolment: 1/02/2008
• Target sample size: 180
• Recruitment status: Not yet recruiting
• URL: http://www.anzctr.org.au/ACTRN12607000514404.aspx
• Study type: Interventional
• Study design: Randomised controlled trial Parallel

Countries of recruitment

Australia

Contacts

• Name: Dr Daniel Steinfort

• Name: Dr Daniel Steinfort

Key inclusion & exclusion criteria

Inclusion criteria: All patients referred to multidisciplinary lung clinic for evaluation and investigation of a solitary pulmonary nodule OR suspected lung cancer
Exclusion criteria: 1.clinical condition precludes investigation
2.Lesions <2cm diameter within 1cm of pleura
3.lesion <1cm diameter anywhere in lung fields
4.Evidence on CT scan of central (endobronchially visible) lesion
5.Other clinical site of disease more amenable to tissue diagnosis
6.Tissue diagnosis considered unnecessary by MDC team
7.Known current diagnosis of lung cancer

Age minimum: -2147483648 No limit
Age maximum: -2147483648 No limit
Gender: Both males and females

Health Condition(s) or Problem(s) studied

Patients with pulmonary nodules or suspected lung cancer

Intervention(s)

Patients will be randomized to undergo either Endobronchial Ultrasound or CT-guided core needle biopsy for the investigation of lung nodules/suspected lung cancer. Once the procedure (each will take approximately 20 minutes to perform) is completed their involvement in the trial will conclude.

Primary Outcome(s)

Diagnostic yield

pneumothorax rate

Secondary Outcome(s)

Radiation dosage received

staging information attained by procedure

Source(s) of Monetary Support

National Health and Medical Research Council

Secondary Sponsor(s)

NHMRC